Main menu

IDH-mutant Adult Gliomas Classification and Grading by Nanopore Technology


The 2021 WHO Classification of Tumors of the Central Nervous System adopted CDKN2A/B deletion marker into the revised grading criteria of IDH-mutant astrocytoma. The CDKN2A/B deletion in IDH-mutant astrocytoma was identified as independent molecular markers of the worst clinical outcomes. Currently, there is no standard assay to assess CDKN2A/B deletion, and current tests such as fluorescence in situ hybridization (FISH), array-based platforms require technical expertise and may not be readily available in routine laboratories. Here we demonstrated the nanopore-based copy number variation approach to identify deletions of CDKN2A/B for glioma diagnosis and grading within 4 hours.

Authors: Thidathip Wongsurawat

Getting started

Buy a MinION starter pack Nanopore store Sequencing service providers Channel partners

Nanopore technology

Subscribe to Nanopore updates Resources and publications What is the Nanopore Community

About Oxford Nanopore

News Company timeline Sustainability Leadership team Media resources & contacts For investors For partners Working at Oxford Nanopore Current vacancies Commercial information BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Spanish flag